<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04457180</url>
  </required_header>
  <id_info>
    <org_study_id>HR-APTN-I-008</org_study_id>
    <nct_id>NCT04457180</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects</brief_title>
  <official_title>A Single Arm, Open and Fixed Sequence Study to Investigate the Pharmacokinetic Effects of Apatinib Mesylate on CYP2C8 Substrate Repaglinide or CYP2B6 Substrate in Advanced Solid Tumor Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study was to assess investigate the pharmacokinetic effects of&#xD;
      Apatinib Mesylate on CYP2C8 Substrate Repaglinide or CYP2B6 Substrate Bupropion and&#xD;
      metabolite Hydroxy bupropion in Advanced solid tumor subjects.&#xD;
&#xD;
      The secondary objective of the study was to assess the safety of Apatinib or/and Repaglinide&#xD;
      and Bupropion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 25, 2020</start_date>
  <completion_date type="Anticipated">October 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 25, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics parameter: Cmax of digoxin</measure>
    <time_frame>through study completion, an average of 16 days</time_frame>
    <description>Peak Plasma Concentration (Cmax) of digoxin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics parameter: AUC of digoxin</measure>
    <time_frame>through study completion, an average of 16 days</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC) of digoxin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics parameter: Tmax of digoxin</measure>
    <time_frame>through study completion, an average of 16 days</time_frame>
    <description>Time of maximum observed concentration (Tmax) of digoxin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics parameter: T1/2 of digoxin</measure>
    <time_frame>through study completion, an average of 16 days</time_frame>
    <description>Half time (T1/2) of digoxin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters CL/F of digoxin</measure>
    <time_frame>through study completion, an average of 16 days</time_frame>
    <description>Total body clearance for extravascular administration (CL/F) of digoxin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics parameter: Vz/F of digoxin</measure>
    <time_frame>through study completion, an average of 16 days</time_frame>
    <description>Volume of distribution (Vz/F) of digoxin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>through study completion, an average of 16 days</time_frame>
    <description>An adverse event is any untoward medical occurrence in a patient or clinical study participant criteria</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Treament</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In phase A, subjects receiving a single dose of Repaglinid orally on day 1 , a single dose of Bupropion orally on day 2 and wash-out for 10 days, then apatinib once daily will be conducted on D5 through D16&#xD;
# In addition, In phase B, subjects receiving a single dose of Repaglinid (in combination with apatinib) orally on day 12 , a single dose of Bupropion (in combination with apatinib) orally on day 13.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib Mesylate</intervention_name>
    <description>Apatinib will be administered daily from on D5 through D16</description>
    <arm_group_label>Treament</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Repaglinide</intervention_name>
    <description>Repaglinide will be administered daily on D1 and D12</description>
    <arm_group_label>Treament</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion</intervention_name>
    <description>Bupropion will be administered daily on D2 and D13</description>
    <arm_group_label>Treament</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Age: 18-70 years old (Include both values); 2. Patients with histopathologically or&#xD;
        cytologically confirmed advanced solid tumor (not necessary to have measurable lesions); 3.&#xD;
        Refractory or intolerant to standard treatment regimens, or no effective standard treatment&#xD;
        regimens available, or the patients refused to use standard treatment plan 4. ECOG PS&#xD;
        score: 0-1; 5. Expected survival ≥ 3 months; 6. Subjects have recovered from other&#xD;
        treatments, at least 6 weeks since the last use of nitrosourea or mitomycin; at least 4&#xD;
        weeks since the last use of small molecule targeted therapy; at least 5 half-lives since&#xD;
        the last use of biological macromolecular therapy; at least 4 weeks since radiotherapy or&#xD;
        surgery; at least 4 weeks since the last use of other cytotoxic or cytostatic drugs; 7.&#xD;
        Major organs must function normally, meeting the following criteria:&#xD;
&#xD;
          1. Hematology (no blood transfusion or blood products within the last 14 days, not&#xD;
             corrected with G-CSF or other hematopoietic colony-stimulating factors):&#xD;
&#xD;
               1. HB≥100 g/L;&#xD;
&#xD;
               2. ANC≥1.5×109/L;&#xD;
&#xD;
               3. PLT≥90×109/L;&#xD;
&#xD;
          2. Blood biochemistry:&#xD;
&#xD;
               1. TBIL≤ 1.25×ULN;&#xD;
&#xD;
               2. ALT and AST≤2.5×ULN;&#xD;
&#xD;
               3. AKPALP≤2.5×ULN;&#xD;
&#xD;
               4. Serum Cr ≤ 1.5 × ULN or endogenous CrCl ≥ 60 mL/min (Cockcroft-Gault formula);&#xD;
&#xD;
               5. Albumin &gt; 30 g/L; 8. Sign the ICF voluntarily, have good compliance, corporate&#xD;
                  with follow-up visits, and follow the study requirements.&#xD;
&#xD;
                  Exclusion Criteria:&#xD;
&#xD;
                  1. Gastric cancer; tumors with risk of bleeding which researchers evaluated. 2.&#xD;
                  Active brain metastasis (medically uncontrolled); 3. Symptomatic third space&#xD;
                  fluid that cannot be controlled by drainage or other methods; 4. Dysphagia,&#xD;
                  chronic diarrhea, or other factors affecting drug intake and absorption; 5.&#xD;
                  Uncontrolled hypertension; 6. Heart rate &lt; 60, Grade II or greater myocardial&#xD;
                  ischemia or myocardial infarction, uncontrolled arrhythmias (QTc interval ≥ 450&#xD;
                  ms in males and ≥ 470 ms in females); 7. Contraindications to Repaglinide and&#xD;
                  Bupropion; 8. NYHA Class III-IV cardiac insufficiency or left ventricular&#xD;
                  ejection fraction (LVEF) &lt; 50% by echocardiography; 9.Abnormal coagulation&#xD;
                  function (INR &gt; 1.5 or prothrombin time (PT) &gt; ULN + 4 s or APTT &gt; 1.5 ULN),&#xD;
                  bleeding tendency or who are currently receiving thrombolytics; 10.&#xD;
                  Arterial/venous thrombosis within 6 months prior to the first dose; 11.Hemorrhage&#xD;
                  and thrombophilia; 12. Major surgery or with severe traumatic injury, fracture,&#xD;
                  or ulcer within 4 weeks prior to the first dose; 13. Abdominal fistula,&#xD;
                  gastrointestinal perforation or abdominal abscess within 6 months prior to the&#xD;
                  first dose; 14. Urine protein ≥ ++ or 24 h urine protein ≥ 1.0 g as indicated by&#xD;
                  urinalysis; 15. Treatment with steroids for more than 50 days, or requires&#xD;
                  chronic steroid use; 16. Use of study drugs in other clinical trials within 4&#xD;
                  weeks prior to the first dose; 27. Use of drugs affected gastric acid secretion&#xD;
                  or cytochrome enzyme CYP2C8、CYP2B6、CYP2D6、CYP3A and transporter OATP1B1 within 4&#xD;
                  weeks prior to the first dose; 18. Use of Chinese medicine, traditional Chinese&#xD;
                  medicine preparation or health products within 2 weeks prior to the first dose;&#xD;
                  19. Unable to hold drugs that may prolong QT interval during the study (such as&#xD;
                  antiarrhythmics); 20.Drug abuse within 12 months before the first dose or&#xD;
                  positive drug screening; 21. Drinking or smoking addiction ; 22.Other factors&#xD;
                  affecting drug absorption, distribution, metabolism, excretion Within 48 hours；&#xD;
                  23.Active hepatitis B (HBV-DNA≥104 or 2000IU/ml) or C (Hepatitis C antibodies are&#xD;
                  positive and HCV-RNA is above the detection limit of the analytical method); 24.&#xD;
                  Active infection requiring antimicrobial therapies (such as antibacterials,&#xD;
                  antivirals, or antifungals); 25. Immunodeficiency, including positive results of&#xD;
                  HIV test or other acquired or congenital immunodeficiencies, or a history of&#xD;
                  organ transplantation; 26. Allergic constitution, or known allergies to drug&#xD;
                  components used in this study; 27. Pregnant or lactating women; 28. Other factors&#xD;
                  that may affect the progress or the conclusion of the study, as determined by the&#xD;
                  investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>pan yueyin, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of University of Science and Technology of China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wang Yuya, Ph.D.</last_name>
    <phone>13918749176</phone>
    <phone_ext>86</phone_ext>
    <email>wangyuya@hrglobe.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of University of Science and Technology of China</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>201203</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>pan yueyin</last_name>
      <phone>13805695536</phone>
      <phone_ext>86</phone_ext>
      <email>yueyinpan1965@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 30, 2020</study_first_submitted>
  <study_first_submitted_qc>June 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2020</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Repaglinide</mesh_term>
    <mesh_term>Apatinib</mesh_term>
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

